MLD publishes world's first chronic plasmalogen-deficient Alzheimer's mouse model Tara SmithJuly 24, 2024
MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial Shawn RitchieFebruary 6, 2024
SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011 Tara SmithJune 6, 2023
MLD's newest manuscript describes the metabolism and tissue distribution of PPI-1011 Tara SmithJune 4, 2022
